Have you noticed how some investors seem to catch the right wave while everyone else is still debating the tide? That is exactly what is happening with Singapore’s Temasek in India right now. Three of its portfolio companies hit the public markets this week and the share prices did not just rise, they jumped. I have been watching these listings closely and the pattern feels hard to ignore.
Why Temasek Keeps Winning in India While Others Exit
Shiprocket listed on Wednesday and the stock finished the day almost 50 percent above its offer price. The IPO itself was oversubscribed nearly a hundred times. That kind of demand does not appear out of thin air. Retail and institutional buyers both piled in, and the logistics company rewarded them immediately. Temasek holds more than a five percent stake. Watching the order books fill up so aggressively made me wonder whether the market had simply been waiting for a clean growth story in that sector.
The day before, dairy producer Milky Mist came to market and by Wednesday it was trading roughly 40 percent above the IPO price after opening at an 18 percent premium. Same investor, same stake size range. Then there is Molbio Diagnostics, which debuted on Monday and still sits about 26 percent higher even after a small pullback. Temasek’s holding there is larger, around 8.74 percent. Add Manipal Health, which listed earlier this month and continues to trade 25 percent above its offer price, and the picture becomes clearer. This is not a one-off lucky punch.
A Consistent Buyer When Others Were Sellers
While many foreign funds have been net sellers of Indian equities for most of the past year, Temasek has done the opposite. Over the last three years it has been a consistent buyer. The fund has put nearly nine billion dollars to work in India during that period. Total exposure now stands at forty-two billion dollars, a four-fold increase over the past decade. Those numbers land with weight. In my view the willingness to keep adding during periods of volatility is what separates long-horizon capital from the more reactive money.
A spokesperson for the firm put it plainly: India remains the best-performing market on a ten-year basis. The same voice added that the team used market swings to top up high-conviction positions. That approach sounds almost old-fashioned in an era of rapid rotation, yet the recent IPO outcomes suggest it still works.
India is our best-performing market on a 10-year basis. We were a net buyer of listed Indian equities during the past financial year, using periods of market volatility to add selectively to high-conviction positions.
Foreign investors as a group sold nearly nineteen billion dollars of Indian equities last year and have continued net selling this year, pushing cumulative outflows past twenty-four billion through mid-August. Against that backdrop Temasek’s steady accumulation stands out. The contrast is almost stark.
What the Fund Sees That Others Appear to Miss
Temasek’s public comments focus on structural drivers rather than short-term sentiment. A large domestic consumer market, a growing middle class, formalization of the economy, infrastructure build-out and deepening capital markets form the core thesis. The fund is already active in consumer, financial services and healthcare. Increasingly it also sees opportunity in industrials, infrastructure and renewables. Those are not flashy AI narratives, yet they map onto real cash-flow businesses that keep expanding.
I find the emphasis on formalization particularly interesting. When more economic activity moves from cash and informal channels into tracked systems, companies with scale and compliance advantages tend to gain share. Shiprocket’s logistics platform and Milky Mist’s dairy distribution both benefit from that shift. Manipal Health rides the same formalization wave inside healthcare delivery. These are not abstract themes. They show up in volume growth and pricing power once the companies are listed.
Market Sentiment Versus Actual Deployment
A recent survey of fund managers ranked India as the least favored market in Asia. Concerns listed included the absence of pure artificial intelligence plays, softer growth numbers, a perceived slow pace of reforms and elevated valuations. One local asset management executive called the survey a clear awakening signal for policymakers. Yet the same voice noted that foreign flows into both debt and equity had improved over the previous two months. Sentiment and actual capital movement are not always synchronized.
Perhaps the most interesting aspect is how Temasek has chosen to ignore the consensus underweight. Instead of waiting for a perfect narrative, the fund has kept buying businesses that already generate cash and operate in expanding addressable markets. The IPO performance this week offers early validation of that choice. Whether the broader foreign investor community eventually follows remains an open question, but the price action so far favors the patient capital.
Breaking Down the Four Recent Listings
Shiprocket’s debut was the most dramatic. Listing at a 35 percent premium and closing nearly 50 percent higher creates an immediate wealth effect for early investors and employees. Logistics in India still has enormous room to formalize last-mile delivery and e-commerce fulfillment. The oversubscription ratio of roughly one hundred times signals that both domestic and overseas buyers wanted exposure to that story.
Milky Mist operates in a more traditional category, dairy products, yet the listing still delivered a strong premium. Branded and packaged dairy continues to gain share from loose milk sales. Temasek’s stake above five percent means the fund participates directly in that transition. The forty percent premium reached on the second day of trading suggests the market is willing to pay for consistent volume growth and brand recognition.
Molbio Diagnostics brings a different angle. Diagnostics demand has structural support from rising healthcare awareness and insurance penetration. An 8.74 percent stake is material. Even after a mild pullback the stock remains meaningfully above the IPO price. That resilience after the initial surge is worth noting. Many new listings fade quickly; this one has held its ground.
Manipal Health, the hospital chain, listed a few weeks earlier and still trades at a 25 percent premium. Healthcare infrastructure remains undersupplied relative to population needs. Ownership by a patient sovereign investor provides a degree of stability that pure financial sponsors sometimes lack. The continued premium indicates investors are comfortable with the long-term occupancy and pricing outlook.
Portfolio Construction Behind the Headlines
Looking across the four names, a pattern emerges. Temasek is not chasing the hottest sector of the moment. Instead it is assembling positions in businesses that benefit from rising formal consumption, better infrastructure and expanding healthcare access. Those themes tend to play out over years rather than quarters. The IPO calendar simply made the returns visible in a compressed timeframe.
In my experience, sovereign wealth funds that stay true to multi-year theses often look out of step during periods of rapid rotation. Yet when the listings arrive and the premiums stick, the quiet accumulation suddenly appears shrewd. The forty-two billion dollar India book did not appear overnight. It was built through successive commitments that survived multiple market cycles.
- Consumer and formalization exposure through dairy and logistics platforms
- Healthcare capacity via hospital and diagnostics assets
- Willingness to increase listed equity holdings during volatility
- Growing interest in industrials, infrastructure and renewables
That list is not exhaustive, but it captures the core of the current posture. The fund has stated it remains constructive on India’s structural growth. The language is measured, yet the capital allocation is decisive.
Contrasting Capital Flows and What They Signal
The broader foreign investor community has withdrawn substantial capital. Nearly nineteen billion dollars left last year and another several billion have exited so far this year. Those outflows create space for investors who are still adding. Temasek has filled part of that space. The result is a visible divergence between the consensus underweight and the actual performance of selected private-to-public transitions.
I keep returning to the survey that labeled India the least favored market in Asia. Lack of AI pure plays, concerns about growth, reform pace and valuations all featured. Those worries are not imaginary. Growth has moderated and valuations in certain pockets remain elevated. Yet the companies Temasek backed managed to list at strong premiums and then extend those gains. The market is discriminating. It is willing to pay for businesses that demonstrate operational traction even when the macro narrative is mixed.
One asset manager observed that foreign flows have improved modestly in the last two months across both debt and equity. That improvement may prove temporary or it may mark the early stage of a broader re-engagement. Either way, Temasek’s earlier commitment already sits in the money.
Structural Themes That Still Attract Patient Capital
The domestic consumer market remains large and is still formalizing. Packaged goods, organized logistics and branded healthcare services all expand as incomes rise and regulatory frameworks tighten. Infrastructure spending continues to create demand for related industrial and services companies. Capital markets themselves are deepening, which improves exit options and secondary liquidity for earlier-stage investments.
Renewables and the broader energy transition form another layer. Temasek has flagged increasing potential in that area. The combination of policy support, falling technology costs and rising electricity demand creates a multi-year runway. Whether the fund increases exposure through listed vehicles or private platforms remains to be seen, but the directional interest is clear.
Financial services complete the picture. Banking penetration, insurance density and capital market participation all have room to grow. Temasek already holds positions in the sector and continues to evaluate new opportunities. The common thread is scale and the ability to compound over long periods.
Lessons From the Recent IPO Wave
First, demand for quality growth stories remains robust even when aggregate foreign flows are negative. Shiprocket’s hundred-times oversubscription is evidence. Second, premiums can stick when the underlying business has clear operating momentum. Third, sizeable stakes held by long-term investors appear to provide a degree of price support after listing. Fourth, the market is capable of distinguishing between thematic hype and businesses with actual cash generation.
Those observations are not revolutionary, yet they are easy to forget when sentiment turns cautious. Temasek’s recent experience offers a practical reminder that selective capital allocation can still produce strong absolute returns.
Looking Ahead Without Over-Promising
No one can guarantee that every future listing will repeat this week’s performance. Markets move, valuations expand and contract, and new risks always appear. What seems more durable is the underlying thesis: a large domestic economy that continues to formalize and urbanize will generate opportunities for scaled operators. Temasek has positioned itself to capture a portion of that opportunity and has already shown the willingness to stay invested through quieter periods.
The next test will be whether the broader investor base begins to re-engage or whether the divergence persists. For now the scoreboard favors the patient approach. Three strong IPO debuts in a single week, plus an earlier healthcare listing that continues to hold its premium, form a tangible data point. In a market often described as out of favor, those results stand out.
I have followed sovereign wealth fund activity in Asia for years and the consistency of Temasek’s India book remains notable. The fund did not invent the structural growth story, yet it has executed on it with unusual discipline. When the public market windows opened this month, the earlier private capital commitments translated into visible gains. That sequence is worth studying for anyone interested in how long-horizon capital actually compounds.
Practical Takeaways for Market Participants
Watch the secondary trading of these newly listed names over the coming months. Sustained premiums would reinforce the quality of the underlying businesses. Track whether other large long-term investors begin to increase India exposure. Observe how policy developments around infrastructure, healthcare and formalization progress. None of these steps requires a dramatic shift in global risk appetite; they simply require attention to operating trends that already exist.
The contrast between survey rankings and actual IPO outcomes this week is instructive. Sentiment can lag reality, and sometimes the lag creates space for those still willing to commit capital. Temasek occupied that space. The share prices of Shiprocket, Milky Mist, Molbio Diagnostics and Manipal Health have recorded the results so far. Whether the pattern continues will depend on execution by the companies themselves and on the broader economic trajectory. For the moment, the Singapore fund’s India strategy looks well timed.
Perhaps the quietest signal is the most important. While many global investors remain underweight, one of Asia’s largest sovereign investors has kept adding. The recent listings simply made that commitment visible to a wider audience. In markets, visibility often arrives after the real work has already been done. That seems to be the case here.
The story is still unfolding. New IPOs will appear, secondary markets will test the premiums, and macro data will continue to arrive. Through it all, Temasek’s forty-two billion dollar exposure and its stated constructive stance provide a clear reference point. India remains a core long-term market for the fund. The gains recorded this week are the latest evidence that the thesis is delivering.
Investors who prefer short-term catalysts may find the narrative too gradual. Those who focus on multi-year compounding may see something different. The difference in time horizon explains much of the current divergence in capital flows. Temasek has chosen the longer path and, at least for now, the path is producing results.
As the dust settles on this week’s listings, the practical question becomes how other capital will respond. Will the strong debuts attract more interest or will the broader underweight posture persist? The answer will shape the next chapter of foreign participation in Indian equities. For Temasek the chapter already underway has delivered tangible gains and reinforced a decade-long commitment. That combination is rare enough to deserve close attention.
The final observation is simple. When a large, patient investor continues to buy while consensus remains cautious, and when the companies it backs then list at meaningful premiums, the market is sending information. Ignoring that information would be a mistake. Temasek’s India experience this month offers a clear data point that structural growth, selective ownership and long holding periods can still generate strong absolute returns even in an environment of mixed sentiment. The next listings and the secondary price action will tell us whether the pattern has further room to run.
